Northern Trust Corp Sells 10,700 Shares of HUTCHMED (China) Limited (NASDAQ:HCM)

Northern Trust Corp cut its holdings in HUTCHMED (China) Limited (NASDAQ:HCM) by 49.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 10,980 shares of the company’s stock after selling 10,700 shares during the quarter. Northern Trust Corp’s holdings in HUTCHMED were worth $158,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Barclays PLC boosted its position in shares of HUTCHMED by 1,483.6% during the fourth quarter. Barclays PLC now owns 2,407 shares of the company’s stock worth $35,000 after purchasing an additional 2,255 shares in the last quarter. Blue Trust Inc. boosted its position in shares of HUTCHMED by 99.9% during the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company’s stock worth $102,000 after purchasing an additional 3,532 shares in the last quarter. Summit Trail Advisors LLC boosted its position in shares of HUTCHMED by 14.4% during the fourth quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company’s stock worth $189,000 after purchasing an additional 1,647 shares in the last quarter. OLD Mission Capital LLC bought a new position in shares of HUTCHMED during the fourth quarter worth $230,000. Finally, Marshall Wace LLP bought a new position in shares of HUTCHMED during the fourth quarter worth $261,000. 8.82% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on HCM. HSBC cut shares of HUTCHMED from a “buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Wall Street Zen cut shares of HUTCHMED from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 22nd.

HUTCHMED Stock Up 8.1%

HCM opened at $14.70 on Wednesday. HUTCHMED has a 12 month low of $11.51 and a 12 month high of $21.50. The firm’s fifty day simple moving average is $14.05 and its 200 day simple moving average is $14.82. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.